Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential

Michael J Lukey; William P Katt; Richard A Cerione

doi:10.1016/j.ccell.2018.04.009

Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential

Cancer Cell. 2018 May 14;33(5):795-797. doi: 10.1016/j.ccell.2018.04.009.

Authors

Michael J Lukey¹, William P Katt¹, Richard A Cerione²

Affiliations

¹ Department of Molecular Medicine, Cornell University, Ithaca, NY 14853, USA.
² Department of Molecular Medicine, Cornell University, Ithaca, NY 14853, USA; Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA. Electronic address: rac1@cornell.edu.

Abstract

Identifying contexts in which cancer cells become addicted to specific nutrients is critical for developing targeted metabolic therapies. In this issue of Cancer Cell, Momcilovic et al. report that suppressed glycolysis following mTOR inhibition is countered by adaptive glutamine catabolism in lung squamous cell carcinoma, sensitizing tumors to glutaminase inhibition.

Publication types

Comment

MeSH terms

Carcinoma, Squamous Cell*
Glutaminase
Glutamine
Glycogen Synthase Kinase 3
Humans
Lung Neoplasms*

Substances

Glutamine
Glycogen Synthase Kinase 3
Glutaminase

Abstract

Publication types

MeSH terms

Substances

Grants and funding